SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on May 22, 2019, covering events that occurred on May 17, 2019. The filing addresses significant changes to the Company's Board of Directors, including the retirement of two directors and the appointment of a new director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignations: Roy T. Tanaka and Seth H.Z. Fischer resigned from the Board of Directors effective May 17, 2019, in connection with their retirement. The Company stated these resignations were not the result of any dispute regarding operations, policies, or practices.
- Stock Option Amendments: In connection with their resignations, both Mr. Tanaka and Mr. Fischer entered into amendments to their stock option agreements. These amendments extended the post-termination exercise period from three months to two years and allowed for share withholding to pay the exercise price.
- Director Appointment: Jerome B. Zeldis was appointed as a director and to the Nominating and Corporate Governance Committee, effective May 17, 2019. His term expires at the next annual meeting of stockholders or until a successor is elected.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to the financial condition of the company were disclosed in this report. The appointment of Dr. Zeldis includes compensation consistent with market practices and the Company's non-employee director policy.
Key Facts for Investor Verification
- Verify the impact of the Board composition changes on the Company's strategic direction.
- Review the full text of the First Amendment to Stock Option Agreements (Exhibits 10.1 and 10.2) to understand the specific terms of the extended exercise periods.
- Confirm the qualifications and background of the newly appointed director, Jerome B. Zeldis.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.